127 related articles for article (PubMed ID: 35475716)
41. Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High-Risk Vascular Disease Treated With Statin Therapy.
Menon V; Kumar A; Patel DR; John JS; Wolski KE; McErlean E; Riesmeyer JS; Weerakkody G; Ruotolo G; Cremer PC; Nicholls SJ; Lincoff AM; Nissen SE
J Am Heart Assoc; 2020 Jan; 9(1):e014328. PubMed ID: 31852422
[TBL] [Abstract][Full Text] [Related]
42. Cinnamon use in type 2 diabetes: an updated systematic review and meta-analysis.
Allen RW; Schwartzman E; Baker WL; Coleman CI; Phung OJ
Ann Fam Med; 2013; 11(5):452-9. PubMed ID: 24019277
[TBL] [Abstract][Full Text] [Related]
43. Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy.
Yu D; Murdoch SJ; Parikh SJ; Marcovina SM; Cobitz A; Chen H; Brunzell JD
Diab Vasc Dis Res; 2006 Dec; 3(3):189-96. PubMed ID: 17160915
[TBL] [Abstract][Full Text] [Related]
44. Prevalence and phenotypic distribution of dyslipidemia in type 1 diabetes mellitus: effect of glycemic control.
Pérez A; Wägner AM; Carreras G; Giménez G; Sánchez-Quesada JL; Rigla M; Gómez-Gerique JA; Pou JM; de Leiva A
Arch Intern Med; 2000 Oct; 160(18):2756-62. PubMed ID: 11025785
[TBL] [Abstract][Full Text] [Related]
45. Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus.
Fischer LT; Hochfellner DA; Knoll L; Pöttler T; Mader JK; Aberer F
Cardiovasc Diabetol; 2021 Apr; 20(1):89. PubMed ID: 33894772
[TBL] [Abstract][Full Text] [Related]
46. Pitavastatin improves glycated hemoglobin in patients with poorly controlled type 2 diabetes.
Huang CH; Huang YY; Hsu BR
J Diabetes Investig; 2016 Sep; 7(5):769-76. PubMed ID: 27181110
[TBL] [Abstract][Full Text] [Related]
47. Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study.
Kawamori R; Node K; Hanafusa T; Atsumi Y; Naito Y; Oka Y
Cardiovasc Diabetol; 2013 Sep; 12():131. PubMed ID: 24011395
[TBL] [Abstract][Full Text] [Related]
48. Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: insights from the CAPITAIN and PREVAIL-US studies.
Chapman MJ; Orsoni A; Robillard P; Hounslow N; Sponseller CA; Giral P
Curr Med Res Opin; 2014 May; 30(5):775-84. PubMed ID: 24328357
[TBL] [Abstract][Full Text] [Related]
49. Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy.
Furuhashi M; Sakuma I; Morimoto T; Higashiura Y; Sakai A; Matsumoto M; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Node K; Ueda S
Cardiovasc Diabetol; 2020 Jun; 19(1):89. PubMed ID: 32539832
[TBL] [Abstract][Full Text] [Related]
50. The impact of outpatient diabetes management on serum lipids in urban African-Americans with type 2 diabetes.
Erdman DM; Cook CB; Greenlund KJ; Giles WH; El-Kebbi I; Ryan GJ; Gallina DL; Ziemer DC; Dunbar VG; Phillips LS
Diabetes Care; 2002 Jan; 25(1):9-15. PubMed ID: 11772894
[TBL] [Abstract][Full Text] [Related]
51. Dyslipidaemia pattern and prevalence among type 2 diabetes mellitus patients on lipid-lowering therapy at a tertiary hospital in central South Africa.
Pitso L; Mofokeng TRP; Nel R
BMC Endocr Disord; 2021 Aug; 21(1):159. PubMed ID: 34365977
[TBL] [Abstract][Full Text] [Related]
52. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
53. Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol.
Nichols GA; Philip S; Reynolds K; Granowitz CB; Fazio S
Diabetes Obes Metab; 2019 Feb; 21(2):366-371. PubMed ID: 30225881
[TBL] [Abstract][Full Text] [Related]
54. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.
Chu NV; Kong AP; Kim DD; Armstrong D; Baxi S; Deutsch R; Caulfield M; Mudaliar SR; Reitz R; Henry RR; Reaven PD
Diabetes Care; 2002 Mar; 25(3):542-9. PubMed ID: 11874944
[TBL] [Abstract][Full Text] [Related]
55. Effect of colesevelam and niacin on low-density lipoprotein cholesterol and glycemic control in subjects with dyslipidemia and impaired fasting glucose.
Davidson MH; Rooney M; Pollock E; Drucker J; Choy Y
J Clin Lipidol; 2013; 7(5):423-32. PubMed ID: 24079283
[TBL] [Abstract][Full Text] [Related]
56. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
[TBL] [Abstract][Full Text] [Related]
57. Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States.
Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Bays HE
Curr Med Res Opin; 2007 Sep; 23(9):2125-33. PubMed ID: 17655813
[TBL] [Abstract][Full Text] [Related]
58. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus.
Yamakawa T; Takano T; Tanaka S; Kadonosono K; Terauchi Y
J Atheroscler Thromb; 2008 Oct; 15(5):269-75. PubMed ID: 18981652
[TBL] [Abstract][Full Text] [Related]
59. Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme a reductase inhibitor treatment of combined dyslipidemia.
McLaughlin T; Abbasi F; Lamendola C; Leary E; Reaven GM
Metabolism; 2002 Oct; 51(10):1355-9. PubMed ID: 12370858
[TBL] [Abstract][Full Text] [Related]
60. Fluctuation between fasting and 2-H postload glucose state is associated with chronic kidney disease in previously diagnosed type 2 diabetes patients with HbA1c ≥ 7%.
Wang C; Song J; Ma Z; Yang W; Li C; Zhang X; Hou X; Sun Y; Lin P; Liang K; Gong L; Wang M; Liu F; Li W; Yan F; Yang J; Wang L; Tian M; Liu J; Zhao R; Chen L
PLoS One; 2014; 9(7):e102941. PubMed ID: 25047354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
